期刊文献+

代谢综合征病人血浆脂联素水平变化的初步研究

A Preliminary Study of Plasma Adiponectin Levels in Subjects with Metabolic Syndrome
下载PDF
导出
摘要 目的探讨代谢综合征(MS)病人血浆脂联素(adiponectin)水平变化及与胰岛素抵抗(IR)的关系。方法筛选MS病人30例及与其年龄、性别相匹配的健康成年人20例为对照组。采用酶联免疫吸附法(ELISA)检测血浆脂联素水平,用HOMA-IR评估IR程度。结果MS组与对照组比较,血浆脂联素水平显著降低[(5.15±2.54)μg/mL与(10.28±5.50)μg/mL,P<0.01];MS组的HOMA-IR指数显著高于对照组[(3.21±1.14)与(1.79±0.98),P<0.05];在MS组,脂联素与体重指数(BMI)、腰围(WC)、三酰甘油(TG)及HOMA-IR呈负相关,与高密度脂蛋白胆固醇(HDL-C)呈正相关,相关系数r值分别为-0.489,-0.548,-0.429,-0.453及0.426(P<0.05)。结论代谢综合征病人血浆脂联素较正常人群降低,且其水平降低可能与IR有关。 Objective To investigate adiponectin levels and the relationship between plasma adiponectin levels and insulin resistance (IR) in subjects with metabolic syndrome (MS). Methods Thirty subjects with MS and 20 age- matched normal subjects were enrolled. Plasma adiponectin levels were measured by ELISA. IR was evaluated by HOMA- IR. Results Plasma adiponectin levels in MS group were significantly lower than that in controls [ (5.15 ± 2.54 )μg/mL vs (10.28 ±5.50) μg/mL (P 〈 0.01 ). HOMA- IR in MS group was significantly higher than that in controls[ (3.21 ± 1.14) vs ( 1.79 ± 0.98, P 〈 0.01 ). Adiponectin was inversely associated with BMI, WC, TG, HOMA- IR and positively associated with HDL - C ( r = - 0. 489, - 0. 548, - 0. 429, - 0. 453 and 0. 426, respectively, P 〈 0.05 for all correlations). Conclusion Plasma adiponectin levels in MS subjects were significantly lower than that in controls and lowered plasma adiponectin levels might be associated with IR.
出处 《中西医结合心脑血管病杂志》 2007年第5期389-391,共3页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
基金 广东省医学科学技术研究基金资助项目(No.A2006205)
关键词 代谢综合征 脂联素 胰岛素抵抗 metabolic syndrome adiponectin insulin resistance
  • 相关文献

参考文献10

  • 1Anderson PJ,Critchley JA,Chan JC,et al.Factor analysis of the metabolic syndrome:Obesity vs insulin resistance as the central abnormality[J].J Int Obes Relat Metab Disord,2001,25(12):1782-1788.
  • 2Carr DB,Utzschneider KM,Hull RL,et al.Intra-abdominal fat is a major determinant of the national cholesterol education program adult treatment panel criteria for the metabolic syndrome[J].Diabetes,2004,53(8):2087-2094.
  • 3Nesto RW.The relation of insulin resistance syndromes to risk of cardiovascular disease[J].Rev Cardiovasc Med,2003,4(suppl 6):s112-s118.
  • 4宋秀霞 ,纪立农 .国际糖尿病联盟代谢综合征全球共识定义[J].中华糖尿病杂志(1006-6187),2005,13(3):178-180. 被引量:611
  • 5Yamauchi T,Kamon J,Waki H,et al.The fat-derived hormone achponeetin reverses insulin resistance associated with both lipoatrophy and obesity[J].Nat Med,2001,7(8):941-946.
  • 6Berg AH,Combs TP,Du X,et al.The adipocyte-secreted protein Acrp30 enhances hepatic insulin action[J].Nat Med,2001,7(8):947-953.
  • 7Kopp HP,Krzyzanowska K,Mohlig M,et al.Effects of marked weight loss on plasma levels of achponeetin,markers of chronic subclinical inflammation and insulin resistance in morbility obesity women[J].Int J Obes,2005,29(7):766-771.
  • 8Yokoyama H,Emoto M,Mori K,et al.Plasma achponectin level is associated with insulin-stimulated nonoxidative glucose disposal[J].J Clin Endocrinol Metab,2006,91(1):290-294.
  • 9Maeda N,Shimomura I,Kishida K,et al.Diet-induced insulin resistance in mice lacking adiponectin /ACRP30[J].Nat Med,2002,8(7):731-737.
  • 10Spranger J,Kroke A,Waki H,et al.Adiponectin and protection against type 2 diabetes mellitus[J].Lancet,2003,361(9353):228-230.

二级参考文献22

  • 1Nesto RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med,2003,4(suppl 6):s11-s18.
  • 2Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol,1994,73:460-468.
  • 3Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med,2003,115(suppl 8A):24s-28s.
  • 4Robins SJ, Rubins HB, Faas FH, et al. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care,2003,26:1513-1517.
  • 5Steinmetz A, Fenselau S, Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes,2001,109:s548-559.
  • 6Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA, 2001,285:1585-1591.
  • 7Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care, 2004,27:1182-1186.
  • 8Lindstrom J, Louheranta A, Mannelin M. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care, 2003,26:3230-3236.
  • 9Tuomilehto J, Lindstrm J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. NEJM, 2001,344:1343-1350.
  • 10Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet,2003,361:2005-2016.

共引文献610

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部